Combinatorial Drug Therapy for ALS Motor Neuron Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for amyotrophic lateral sclerosis (ALS) are limited, with no clear diagnostic test and few effective pharmacologic therapies available, leading to a need for novel and effective therapies to address the progressive degeneration of motor neurons and associated symptoms.
Innovation Solution
The development of novel combinatorial therapies using drug combinations such as baclofen and acamprosate, torasemide and baclofen, cinacalcet and mexiletine, or sulfisoxazole and torasemide, which are administered alone or in combination with riluzole, to provide protective effects against glutamate toxicity and delay motor neuron degeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional single-drug therapies are used for ALS, then treatment simplicity is maintained, but therapeutic efficacy is insufficient to slow disease progression
Solution Approach 1:
The patent combines multiple drugs with different mechanisms of action into a single therapeutic regimen. Specifically, it integrates riluzole (which modulates glutamate activity) with edaravone (a free radical scavenger) and/or vitamin E (an antioxidant), creating a multi-target therapy that addresses different pathogenic mechanisms of ALS simultaneously, thereby improving therapeutic efficacy while presenting a unified treatment approach
2Measurement precision
If no diagnostic test is available, then diagnostic simplicity is maintained, but diagnostic precision is insufficient to confirm ALS
Solution Approach 1:
The diagnostic approach is segmented into multiple independent assessment components: clinical evaluation of motor neuron symptoms, neurological examination findings, electrodiagnostic testing (EMG/NCS), and exclusion of alternative diagnoses. This segmentation allows for systematic evaluation of different aspects of the disease presentation, improving diagnostic precision through a structured multi-step process rather than relying on a single complex test
3Reliability
If current limited therapies are used, then treatment availability is maintained, but disease progression control is insufficient
Solution Approach 1:
The patent creates a universal therapeutic framework that can be adapted to different ALS patients based on their specific disease characteristics. The core regimen of riluzole combined with edaravone and/or vitamin E serves as a versatile base that addresses multiple pathogenic mechanisms (glutamate excitotoxicity, oxidative stress, free radical damage) simultaneously, allowing the treatment to be effective across different ALS subtypes and progression rates while maintaining a consistent core approach
Data Source
Figure 1
Figure 2A~2C
Figure 3~4
AI summary
The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorialtherapiesfor treating amyotrophic lateral sclerosisor a related disorder.